PMID: 484256Jan 1, 1979Paper

Non-selective and selective beta-1-adrenoceptor blocking agents in the treatment of hyperthyroidism

Acta Medica Scandinavica
O R NilssonS Almqvist

Abstract

Treatment for one month with propranolol or atenolol, a selective beta-1-adrenoceptor blocking agent, was evaluated in 20 hyperthyroid patients. The patients improved to the same extent on either drug, as shown by a clinical diagnostic index. Basal metabolic rate decreased by 11% during both treatments, while it was unchanged in seven untreated hyperthyroid controls. Thyroxine concentration did not change during any treatment. During propranolol treatment T3 decreased from 4.6 to 3.9 nmol/l, while no changes were observed during atenolol treatment or in the control group. No significant changes were seen in free T4, free T3 or rT3 concentrations on any treatment, although free T3 was observed to decrease slightly during propranolol treatment. Thus, the improvement of the clinical symptoms of hyperthyroidism cannot be explained by diminished thyroid hormone concentrations in serum, since the reduction was small during propranolol and absent during atenolol treatment.

References

Oct 1, 1975·British Journal of Clinical Pharmacology·I Ramsay
Aug 13, 1977·Lancet·P TheiladeK Siersbaek-Nielsen
Mar 27, 1976·Lancet·A BurgerL Braverman
Mar 1, 1978·The Journal of Clinical Endocrinology and Metabolism·C W ZwillichJ V Weil
May 1, 1977·The Journal of Clinical Endocrinology and Metabolism·R P VerhoevenM A Schalekamp
Jun 1, 1977·Clinical Endocrinology·G LottiA Masala
Jul 1, 1978·Clinical Endocrinology·J SaundersP H Sönksen
Oct 1, 1975·British Journal of Clinical Pharmacology·J K Nelson, D G McDevitt
Apr 1, 1976·British Journal of Clinical Pharmacology·L E MurchisonW R Ferrier
Dec 1, 1975·The Journal of Clinical Endocrinology and Metabolism·I J ChopraD H Solomon
Aug 1, 1977·The Journal of Clinical Endocrinology and Metabolism·W M Wiersinga, J L Touber
Jan 1, 1975·Metabolism: Clinical and Experimental·L P GeorgesJ J Canary
Nov 1, 1975·The Journal of Clinical Endocrinology and Metabolism·I J ChopraD H Solomon
Mar 19, 1966·Lancet·G Howitt, D J Rowlands
May 17, 1969·Lancet·R G ShanksD A Montgomery
Jul 1, 1969·Acta Endocrinologica·D R HaddenJ A Weaver
Jun 1, 1971·Annals of Internal Medicine·W GrossmanL Dexter
Mar 24, 1972·Biochemical and Biophysical Research Communications·T MitsumaC S Hollander

❮ Previous
Next ❯

Citations

Jan 1, 1991·Thyroid : Official Journal of the American Thyroid Association·W M Wiersinga
Nov 18, 1982·The New England Journal of Medicine
Jan 1, 1982·European Journal of Clinical Pharmacology·B HallengrenE Wåhlin-Boll
Apr 1, 1981·International Journal of Dermatology·J E Freitas
Jan 1, 1983·Acta Medica Scandinavica. Supplementum·O R Nilsson, B E Karlberg
Sep 1, 1980·Clinical Endocrinology·J HowP D Bewsher
Jan 1, 1991·European Journal of Clinical Pharmacology·P H Davies, J A Franklyn
Jun 1, 1982·British Journal of Clinical Pharmacology·N R PedenJ Crooks
Mar 1, 1990·Clinical Endocrinology·O EberP Költringer
Jan 1, 1982·European Journal of Clinical Pharmacology·A AroH Sundquist
Dec 1, 1981·British Journal of Clinical Pharmacology·G R JonesD Wynford-Thomas
Jan 1, 1982·Journal of Endocrinological Investigation·S RassuM Langer
Oct 1, 1980·European Journal of Clinical Pharmacology·O R NilssonL Tegler
Sep 1, 1983·Scandinavian Journal of Clinical and Laboratory Investigation·G LindstedtA Svanborg
Jul 1, 1992·The American Journal of Medicine·D L Geffner, J M Hershman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.